Literature DB >> 28164086

Special issue: "MET as actionable target in cancer therapy".

Patrick C Ma1.   

Abstract

Entities:  

Year:  2017        PMID： 28164086      PMCID： PMC5253282          DOI： 10.21037/atm.2017.01.10

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  21 in total

Review 1.  Targeting MET in cancer: rationale and progress.

Authors:  Ermanno Gherardi; Walter Birchmeier; Carmen Birchmeier; George Vande Woude
Journal:  Nat Rev Cancer       Date:  2012-01-24       Impact factor: 60.716

2.  Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer.

Authors:  Giorgio V Scagliotti; Silvia Novello; Joan H Schiller; Vera Hirsh; Lecia V Sequist; Jean-Charles Soria; Joachim von Pawel; Brian Schwartz; Reinhard Von Roemeling; Alan B Sandler
Journal:  Clin Lung Cancer       Date:  2012-03-21       Impact factor: 4.785

3.  Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.

Authors:  Garrett M Frampton; Siraj M Ali; Mark Rosenzweig; Juliann Chmielecki; Xinyuan Lu; Todd M Bauer; Mikhail Akimov; Jose A Bufill; Carrie Lee; David Jentz; Rick Hoover; Sai-Hong Ignatius Ou; Ravi Salgia; Tim Brennan; Zachary R Chalmers; Savina Jaeger; Alan Huang; Julia A Elvin; Rachel Erlich; Alex Fichtenholtz; Kyle A Gowen; Joel Greenbowe; Adrienne Johnson; Depinder Khaira; Caitlin McMahon; Eric M Sanford; Steven Roels; Jared White; Joel Greshock; Robert Schlegel; Doron Lipson; Roman Yelensky; Deborah Morosini; Jeffrey S Ross; Eric Collisson; Malte Peters; Philip J Stephens; Vincent A Miller
Journal:  Cancer Discov       Date:  2015-05-13       Impact factor: 39.397

4.  Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer.

Authors:  Lecia V Sequist; Joachim von Pawel; Edward G Garmey; Wallace L Akerley; Wolfram Brugger; Dora Ferrari; Yinpu Chen; Daniel B Costa; David E Gerber; Sergey Orlov; Rodryg Ramlau; Susan Arthur; Igor Gorbachevsky; Brian Schwartz; Joan H Schiller
Journal:  J Clin Oncol       Date:  2011-07-18       Impact factor: 44.544

5.  Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas.

Authors:  L Schmidt; F M Duh; F Chen; T Kishida; G Glenn; P Choyke; S W Scherer; Z Zhuang; I Lubensky; M Dean; R Allikmets; A Chidambaram; U R Bergerheim; J T Feltis; C Casadevall; A Zamarron; M Bernues; S Richard; C J Lips; M M Walther; L C Tsui; L Geil; M L Orcutt; T Stackhouse; J Lipan; L Slife; H Brauch; J Decker; G Niehans; M D Hughson; H Moch; S Storkel; M I Lerman; W M Linehan; B Zbar
Journal:  Nat Genet       Date:  1997-05       Impact factor: 38.330

6.  A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin.

Authors:  Patrick C Ma; Erik Schaefer; James G Christensen; Ravi Salgia
Journal:  Clin Cancer Res       Date:  2005-03-15       Impact factor: 12.531

7.  Met receptor overexpression and oncogenic Ki-ras mutation cooperate to enhance tumorigenicity of colon cancer cells in vivo.

Authors:  Isolde Seiden Long; Kathy Han; Ming Li; Senji Shirasawa; Takehiko Sasazuki; Michael Johnston; Ming-Sound Tsao
Journal:  Mol Cancer Res       Date:  2003-03       Impact factor: 5.852

Review 8.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

9.  Mechanisms of Resistance to Epidermal Growth Factor Receptor Inhibitors and Novel Therapeutic Strategies to Overcome Resistance in NSCLC Patients.

Authors:  Luping Lin; Trever G Bivona
Journal:  Chemother Res Pract       Date:  2012-08-29

10.  Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer.

Authors:  Z Tang; R Du; S Jiang; C Wu; D S Barkauskas; J Richey; J Molter; M Lam; C Flask; S Gerson; A Dowlati; L Liu; Z Lee; B Halmos; Y Wang; J A Kern; P C Ma
Journal:  Br J Cancer       Date:  2008-09-16       Impact factor: 7.640
View more
  3 in total

Review 1.  MET Activation and Physical Dynamics of the Metastatic Process: The Paradigm of Cancers of Unknown Primary Origin.

Authors:  Giulia M Stella; Silvia Benvenuti; Alessandra Gentile; Paolo M Comoglio
Journal:  EBioMedicine       Date:  2017-09-21       Impact factor: 8.143

Review 2.  Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy.

Authors:  Zuan-Fu Lim; Patrick C Ma
Journal:  J Hematol Oncol       Date:  2019-12-09       Impact factor: 17.388

3.  MicroRNA-133b expression inversely correlates with MET and can serve as an optimum predictive biomarker for patients of colorectal cancer.

Authors:  Yihang Guo; Gui Hu; Biao Xie; Ni Gong
Journal:  Transl Cancer Res       Date:  2021-01       Impact factor: 1.241
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.